Skip to main content
Advertisement
Advertisement

APRE

APRE logo

Aprea Therapeutics, Inc. Common stock

0.78
USD
Sponsored
0.00
-0.04%
Sep 24, 15:15 UTC -4
Closed
exchange

Pre-Market

0.78

0.00
+0.04%

Aprea Therapeutics, Inc. Common stock Profile

About

Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, p53. The Company's lead drug candidate, APR-246, a first-in-class small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes, acute myeloid leukemia as well as additional hematologic and solid tumor malignancies. Aprea Therapeutics Inc. is based in Boston, Massachusetts.

Info & Links

CEO

Oren Gilad

Headquarters

3805 Old Easton Road
DOYLESTOWN, PA 18902, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

http://www.aprea.com

Auditor

EisnerAmper LLP

Share holders

132

Employees

8

Aprea Therapeutics, Inc. Common stock Statistics

Valuation Measures

Market Capitalization2

9.82M

Enterprise Value

-31.41M

Enterprise Value/EBITDA(ttm)

2.38

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

32.24

Price to Book(mrq)

0.24

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

25.00%

Operating Margin(ttm)

-4405.59%

Profit Margin(ttm)

-18397.01%

Return on Equity(ttm)

-47.60%

Return on Invested Capital(ttm)

-64.22%

Return on Assets(ttm)

-40.97%

Income Statement

Revenue(ttm)

5.10K

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

5.10K

EBITDA(ttm)3

-13.20M

Net Income Available to Common(ttm)

-12.31M

Diluted EPS(ttm)

-1.08

Share Statistics

Beta (5Y Monthly)

1.54

52-Week Change

-45.09%

S&P 500 52-Week Change

19.38%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

12.59M

Dividend Yield

0.00%

Float4

11.27M

% Held by Insiders

10.49%

% Held by Institutions

34.19%

Balance Sheet

Total Cash(mrq)

41.23M

Total Cash Per Share(mrq)

3.27

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

13.55%

Quick Ratio(mrq)

13.56%

Book Value Per Share(mrq)

3.10

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.11

Free Cash Flow(ytd)

-6.05M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement